Spotlight On... NICE changes its tune on J&J's Zytiga for pre-chemo prostate cancer treatment; FDA rejects Eagle's clot drug; Roche integrates diabetes app with Apple Health; and more...

The U.K. cost watchdogs at the National Institute for Health and Care Excellence (NICE) have kept a stiff upper lip when it comes to Johnson & Johnson's ($JNJ) prostate cancer drug Zytiga, saying that it couldn't fund the med for pre-chemo treatment because it was too expensive. Now J&J has stepped forward with a new payment deal, so NICE is changing its tune. The cost gatekeeper agreed to cover Zytiga after a reduction in the drug's list price, and as long as J&J covers the med at full cost after patients' first 10 months of treatment. The decision comes as a win for Zytiga, which is facing some stiff competition from Astellas' rival med Xtandi. Story

> The FDA has turned down Eagle Pharmaceuticals' ($EGRX) Kangio, a med meant to prevent blood clots in certain patients undergoing heart surgery. More

> Roche ($RHHBY) is integrating its diabetes app, Accu-Chek Connect, with Apple Health, meaning it'll now allow patients to share the blood glucose and carbohydrate data they collect with the iPhone system. Report

> There are lucrative opportunities for new players to invigorate a "stagnant" bipolar drug market, according to research and consulting firm GlobalData. More (sub. req.)

> The government of Wales has overruled a decision by the U.K.'s cost watchdogs not to recommend Celgene's ($CELG) pancreatic cancer drug, Abraxane, for routine use by the NHS. Report

And Finally... Chinese authorities have vowed to crack down on the black market sale of vaccines. More

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.